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Clinical Applications of
Prostaglandins in Dogs and Cats
by Edward C. Briles, DVM*
Lawrence E. Evans, DVM, PhD * *
In the biological sciences today there are few
substances that generate as much interest as
prostaglandins. They have found widespread
use in veterinary medicine, yet are only ap-
proved by the FDA for specific uses in cattle
and horses. However, practical applications in
the dog and cat have been reported by clini-
cians and have been evaluated in clinical
research projects.
The purpose of this paper is, first, to provide
an overview of these areas where prostaglan-
dins may be utilized in canine and feline prac-
tice. Secondly, owing to the fact of its recent
emergence on the veterinary medical scene, a
brief background on prostaglandins will be in-
eluded to facilitate understanding.
BACKGROUND
Prostaglandins are naturally occurring
substances classified as autocoids, from the
Greek autos ("self') and akos ("medicinal
agent"), and referred to as parahormones,
humoral mediators, or local hormones because
they are not systemically circulating hor-
mones, but act only on the local level. They are
produced by most biological tissues and are
detectable in most body fluids. Members of the
prostaglandin family have specific reproduc-
tive functions and also participate as mes-
senger-type agents in the function of nearly
every physiologic system in the body.l Their
actions are believed to be mediated by cyclic
AMP and cyclic G MP.2
In 1936, Von Euler derived the name "pro-
staglandin" from the prostate gland to identify
a lipid-soluble acid that he had found to be the
active substance in human semen which had
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previously been shown to make smooth muscle
contract. 3 •4 It wasn't until 1957 that two pro-
staglandins (PGE l , PGF la) were isolated in
pure crystalline form and soon more pro-
staglandins were characterized, all of which
were found to be 20-carbon unsaturated car-
boxylic acids with a cyclopentane ring.
Thereafter, it was found that all prostaglan-
dins are derived from linoleic and arachidonic
fatty acids; arachidonate is in the phospho-
lipids of cell membranes of all mammalian
tissues. 5
There are several main classes of pro-
staglandins: E,F,I,A,B,C,D, distinguished by
the constituents of the cyclopentane ring. The
main classes are further subdivided in accord
with the number of double bonds in the side
chains. 3 The most biologically active com-
pounds are PGE2, PGF2a, TXA, and PGI2 all
of wh~ch have a pair of double bonds and are,
therefore, designated as the 2 series. 5 The E
and Fa Groups are the most abundant in
reproductive tissues, especially PGE2 and
PGF2a , with only prostaglandin F2a and its
analogues available commercially for
veterinary use in this country. PGF2a is prob-
ably the natural uterine luteolytic factor in
most species.
The first product on the market was the
THAM salt of PGF2a, dinoprost trometha-
mine (Prostin F2alphaR-Upjohn Co.). It is
labelled for use only in horses to control the
time of estrus in cyling mares and to treat
mares with prolonged diestrual periods. The
approved dosage is 1 mg/l00 lbs. (0.022
mg/kg) administered as a single intramuscular
injection. The Upjohn Co. subsequently came
out with another dinoprost product
(LutalyseR ) which is identical to Prostin
F2alpha except it is labelled for synchroniza-
tion of estrus among beef cattle and nonlac-
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tating dairy heifers, and for abortion of feedlot
heifers before 100 days of gestation. The ap-
proved dosage is 25 mg as a total dose ad-
ministered intramuscularly. Another com-
mercial product is prostalene (Synchro-
ceptR-Diamond) which is a PGF2a analogue
labelled for use only in horses at a dosage of 5
ug/kg.
Besides the approved uses, PGF 2a is used in
the bovine therapeutically for unobserved
estrus, pyometra, mummified fetus, luteinized
cysts, and induction of parturition. 6 Other
unapproved uses have also been recognized in
the equine. 7 ,8 PGF2a has been used for induc-
tion of parturition in swine. 9
Women of child-bearing age, asthmatics,
and persons with bronchial and other
respiratory problems should be very careful
when handling this drug because prostaglan-
dins of the F series are effective abortifacients
and potent bronchoconstrictors in human
beings.
Uses of prostaglandin reported in this paper
are of the dinoprost tromethamine product
and are in nonapproved species based solely
on results of experimental use. The FDA does
not sanction such uses, therefore, the
veterinarian assumes full responsibility.
ABORTION
It has been established that endogenous
PGF2a of uterine origin in the cow is in-
strun1.ental in terminating luteal function in
the nonpregnant animal thus returning it to
heat. PGF2a release from the uterus is also im-
portant for the prepartum lysis of the corpus
luteum which removes the progesterone block
and for increasing the contractile strength of
the uterine musculature prior to parturition. 10
Consequently, exogenous PGF2a has proven
to be an effective abortifacient in cows. In dogs
and cats it is known that prostaglandins play
an important role in reproductive function but
that role is not nearly as well worked out as it
is in the bovine.
PGF2a can be used to terminate gestation in
the bitchll . 12 and queen. 13 One study has
reported that PGF2a given intramuscularly to
pregnant beagle bitches from day 33 to day 53
of gestation at a dosage of either 20 ug/kg
every 8 hours or 30 ug/kg every 12 hours for 72
hours (180 ug/kg total dose) will cause the
fetuses to abort within 56 to 80 hours after
treatment begins. ll It was shown that com-
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plete luteolysis was induced and abortion oc-
curred when plasma progesterone was
depressed to 0.6-1.4 ng/ml from pretreatment
levels of 3-40 ng/nll. 11
It has been the authors' experience that the
proper length of treatment (six injections, one
every 12 hours) must be maintained to pro-
duce a successful abortion. In an earlier study
luteolysis and abortion were not produced
when a larger total dose (250 ug/kg) was given
intraveneously within a seven hour period. 14
It also seems imperative that the treatment
be delayed until the mid to late gestation
period since the early corpora lutea in the bitch
are more refractory to PGF2a' Similarly, in
cattle doses of PGF2a must be given after day
five of the estrous cycle in order to get
luteolysis. 15 An hypothesis has been
proposed16 and supported17 that explains the
resistance of the newly formed corpus luteum
by the fact that "the preovulatory surge of LH
saturates the regulatory units of the luteal cells
and that it is this bound hormone which
protects the young corpus luteum." Previous-
ly, corpus luteum receptors for PGF2a were
identified. 18
It is not surprising that this regimen of ex-
ogenously administered PGF2a (every 12
hours for three days) is effective in producing
luteolysis in the bitch when considering the en-
dogenous PGF2a release patterns associated
with luteolysis in other species. Parallels tend
to appear between the natural release of
PGF2a and the above-mentioned regimen in
dogs. In the bovine the production and release
of PCF2a by the uterus is known to be pulsatile
and precise. During the estrous cycle PGF2a is
released for two to three days as rapid pulses
with a duration of one to five hours prior to
and during luteolysis, which is indicated by
decreasing levels of plasma progesterone. 19
The exact mechanism for PGF2a induced
luteolysis has not been worked out in any
species but some theories are as follows: an-
tagonism with LH or prolactin; promotion of
fragility in lysosomes; contractile effect on the
utero-ovarian vein, resulting in reduced blood
flow through the ovary; decreased stores of the
progesterone precursors, cholesterol esters; or
decreased esterase activity.
PCF2a also induces strong myometrial con-
tractions in the bitch which plays a role in the
induced abortion along with at least a de-
creased luteal function.
91
It has also been reported that a one-shot
dosage of 1 mg/kg PGF2a in the bitch is an
effective abortifacient. 12 However, details con-
cerning the application of this dosage are not
available.
The veterinarian is often faced with the
client who believes his bitch may have been
bred to an undesirable male dog. The client
desires that something be done to remedy the
situation. If more than two or three days have
elapsed since the misalliance, a mismating
shot of estrogens (0.5-1 mg/lb stilbesterol or
0.5-2 mg ECP) might be ineffective or
undesirable. The owner may not want the
bitch spayed and would rather not put the dog
through a pregnancy. In this situation a
PGF2a induced abortion may be indicated.
First, however, the pregnancy should be
confirmed by digital palpation between days
25-35 of gestation. If palpation cannot
confirm the pregnancy, ultrasonography may
be used as early as the 29th day or radiographs
may be taken after day 42 of gestation.
If the dog is indeed pregnant and in good
health, free of any respiratory problen1s, it can
be started on a regimen of PGF2a at 25-30
ug/kg every 12 hours 1M or SQ for 72 hours
(total of 6 treatments) starting no earlier than
the 33rd day of gestation. Priming the dog
with 0.1-2 mg ECP given 1M about 24 hours
prior to starting the PGF2a treatment may in-
crease the abortifacient effect. Although not
originally described as part of the abortifacient
procedure, estradiol-17B injected into ewes
has elicited marked synthesis and release of en-
dogenous PGF2a. 21 Estrogens also help
prepare the uterus for contraction by increas-
ing myometrial motility, and in some species
estrogens stimulate the release of oxytocin
from the posterior pituitary gland. 20 However,
it should be stated that PGF2a without
estrogen priming will induce abortions.
The dog should be hospitalized and food
withheld 24 hours prior to beginning the treat-
ment regimen. In the original study11 no ob-
vious nor consistent systemic side effects were
noted, but it should be expected that the dog's
respiratory rate will increase, usually within
five minutes after injection, and there will be
vomition and defecation. There is usually not
more than one episode of emesis and defeca-
tion per injection. The panting should subside
within 45 minutes. The half-life of PGF2a in
the body is very short being about eight
minutes in the bovine. 22 It has been reported
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that 80% of injected PGF2a is excreted in the
urine within six hours in the bovine. 4 A mild
drop in body temperature (i-2°F) similar to
that preceding normal parturition may be
noted. 11 After the second or third injection the
bitch may display vigorous nest building
behavior. Fetal expulsions should be expected
to occur approximately 56-80 hours after the
first PGF2a injection with the bitch 'showing no
signs of difficulty. 11
Some dogs may not abort at this dosage and
treatment length because of individual
variability in hormonal patterns. 11,14 This in-
dividual variability may necessitate a more
flexible schedule of treatment such as a longer
treatment period or higher dose. Not enough
data is available to draw any statistics on the
success of each possible treatment regimen.
The subcutaneous median lethal dose for
PGF2a in the beagle bitch has been reported to
be 5.13 mg/kg. 12 At this dose the clinical signs
of toxicosis include excessive salivation,
vomiting, diarrhea, hyperpnea, ataxia, and
pupillary dilatation and then pupillary con-
striction. The effects were maximal from
90-120 minutes after treatment and death oc-
curred in a few hours (2-11). The toxicological
signs resembled those of endotoxic and
neurotoxic shock syndromes. 12
Some minor side effects were noted incon-
sistently at dosages greater than or equal to
0.444 mg/kg given 1M. These signs included:
mild locomotor incoordination, rubbing the
face wjth the forefeet, slight CNS depression,
micturition and slight hyperthermia in addi-
tion to hyperpnea, vomiting, and defecation. 23
When PGF2a was given IV at doses as low as
30 ug/kg emesis was caused consistently in 30
seconds and slight incoordination and illness
followed. 14
From the data available on side effects it is
apparent that PGF2a is better suited for 1M or
SQ injection, because it is absorbed more
slowly. The most consistent side effect ob-
served was the increase in respiratory rate
which can be accounted for by the fact that
PGF2a is a potent bronchoconstrictor and as
such should not be used in dogs with res-
piratory dysfunction. Vomiting also appeared
often, but at the dosage of 30 ug/kg 1M or SQ
it does not always occur. The emesis at this
dosage is not usually characterized by
wretching or illness, but occurs rapidly
without much effort or discomfort on the part
of the dog. The vomiting and defecation usual-
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ly become less pronounced with each
treatment. 11,14 The emesis and defecation are
due to the stimulatory effect of PGF2a on
smooth muscle.
At a dosage of 30 ug/kg there is over a 100X
margin of safety (MLD = 5.13 mg/kg) which
is quite acceptable. If, however, a one-injec-
tion luteolytic dosage of 1 mg/kg is used the
margin of safety is only 5X, which is not accep-
table. The rationale for using the larger dose is
that only one injection is needed; however, it
has been shown that a dosage of 30 ug/kg given
every 12 hours for six treatments elicits effec-
tive luteolysis, and abortion is achieved with
minimal side effects11 and more closely cor-
responds to the body's own natural release of
PGF2a from the uterus prior to regression of
the corpora lutea. 19 Prostaglandin does not
have a cumulative effect in the body because it
is rapidly metabolized and excreted from the
body. It is vital whenever using PGF2a in the
dog or cat to compute the dose accurately by
weighing the patient.
In the queen it has been reported that one or
two subcutaneous injections of PGF2a 24
hours apart at the dosage of 0.5-1 mg/kg will
induce abortion if given after the 40th day of
gestation. 13 Fetal expulsion occurred within 24
hours of the first injection or within 24 hours of
the second injection, if needed. Within 15
minutes after injection cats were noted to
defecate in their litter boxes. Other side effects
were minimal. As in dogs, cats with com-
promised respiratory function should not be
given PGF2a .
In another study two S.Q. injections of
PGF2a 24 hours apart at a dosage of 0.5-1
mg/kg after the 40th day of gestation did not
result in abortion, but only partialluteolysis. 24
Instead, after day 51 of gestation a regimen of
ACTH followed by PGF2a 24-96 hours later
was shown to induce complete luteolysis and
abortion. Using smaller doses of PGF2a and
spreading them out over six treatments as in
the dog has not been reported in the cat.
Presently, it is not clear whether the PGF2a-
induced abortions in cats are due to luteolysis
of the corpus luteum of pregnancy or the result
of PGF2a-induced myometrial contractions.
Most studies have demonstrated only a partial
decrease in luteal function after exogenous
PGF2a administration. 24,25,26 It is likely that
abortion occurred due to the "oxytocic" effect
on the uterus in the presence of decreased
luteal function.
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A toxic dose of PGF2a injected SQ has been
reported in the cat at approximately 5.0
mg/kg. 25 Clinical signs of toxicosis noted were
ataxia, respiratory distress, muscle tremors,
and loose bowel movements. 25 The cat does
not appear to be as sensitive to prostaglandins
as is the dog.
INDUCTION OF PARTURITION
There have been no studies on the use of
prostaglandins to induce parturition in the
dog; however, since it has been shown that
prostaglandins play such an important role in
the normal physiology of parturition in the
dog,2° and since it terminates pregnancy in the
mid to late phase of gestation, it seems likely
PGF2a alone or in combination with oxytocin,
estrogen, or dexamethasone would be effective
in inducing parturition. During normal par-
turition it has been suggested that prostaglan-
dins may act on the pituitary gland of the dam
resulting in the release of oxytocin, act on the
placenta to inhibit progesterone production
and release relaxin, and act on the ovary to
release relaxin. 20
In the cat the mechanism of parturition has
not been studied and hormonal interrelation-
ships are essentially unknown, yet it is likely
that the cat does not differ significantly from
other species and prostaglandin alone or in
combination, as in inducing abortion, may be
effective in inducing parturition. In one study
PGF2a (0.50-1.0 mg/kg) given in two doses 24
hours apart to cats over 55 days of gestation in-
duced parturition resulting in live kittens that
were normal and healthy. 13 The queens pro-
duced milk at parturition and suckled their
young. One case report appears in the litera-
ture27 where a nine-month old queen on the
70th day of gestation, with a history of a clear
vaginal discharge on day 65 without obvious
signs of labor, was administered two SQinjec-
tions of PGF2a 24 hours apart at a dose of 0.5
mg/kg. Two hours after the second dose the
first kitten was born dead and three live kittens
followed within 90 minutes. The three kittens
received adequate milk and were reared suc-
cessfully. The queen experienced an increased
respiration rate, restlessness, and inconti-
nence during the treatment.
Prostaglandins can be used in combination
with oxytocin to adequately induce labor in
women. 28 They can also be used to effectively
induce parturition in cows,29 SOWS,9 does,30
and ewes. 31
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PSEUDOPREGNANCY
It has been reported that 0.5 mg/kg (total
dose) of PGF2a given SQ to 40 clinically false
pregnant bitches of various breeds and ages
resulted in regression of the symptoms of false
pregnancy in 37 animals. 32 The symptoms in-
cluded: galactorrhea, mammary enlargement,
mothering behavior, nest building, and labor
pains. The dogs returned to normal behavior
in about seven to eight days after the treat-
ment. The dose of PGF2a had to be repeated
in four cases to be effective. The side effects
reported were very minimal. Presumably the
effectiveness of PCF2a in treating pseudopreg-
nancy in the bitch is due to its luteolytic effect.
In the cat one study has been reported sug-
gesting that PGF2a (0.5-5.0 mg/kg SQ) given
during the early luteal phase would be ineffec-
tive for the premature termination of
pseudopregnancy.25
SUBINVOLUTION OF THE
PLACENTAL SITES
It has been reported that PGF2a can be used
to treat subinvolution of the placental sites in
the bitch, where chronic post-partum uterine
hemorrhage is a problem, by using one dose at
0.1-0.25 mg/kg or at the rate of 25 ug/kg every
12 hours until six injections have been given. 7
The mechanism of action of PGF2a in this case
was not reported.
UTERINE DISEASE
Another use of PGF2a in dogs is in the treat-
ment of uterine disease. It has been reported
that PGF2a at 250 ug/kg SQ was used suc-
cessfully in 14 of 16 cases to medically treat-en-
dometritis and pyometra. 33 Successful medical
treatment resulted in remission of clinical
signs within 30 days post-treatment with no
surgical intervention, but supportive therapy
and antibacterials were used as needed. Suc-
cess was achieved in five of the six endometritis
cases, in two of the three metritis cases, and in
seven-~ofthe seven pyometra cases. 33 10 out of
the 16 cases needed more than one treatment,
ranging from 2 to 4 treatments. The study did
not report the time interval between treat-
ments, but stated that there was "retreatment
at a later date." All but one of the pyometra
cases appeared to be open pyometras. In a
follow-up of nine intact bitches to assess post-
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PGF2a fertility all nine had a subsequent
estrus period. Five of nine bred at an estrus
after treatment were subsequently pregnant.
Two of the five whelped normal litters. It did
not state the outcome of the other three preg-
nant bitches. The study suggests that PCF2a
therapy may offer an alternative to surgery in
breeding bitches, in cases where surgery may
not be desired by the pet owner, and in
animals that might otherwise be questionable
surgical risks. 33
Two case reports on the use of PCF2a to
treat pyometra in the bitch appear in the litera-
ture. In one case an open pyometra in a two
year old bassett hound was treated with one
1M injection of PGF2a at a dose of 0.2 mg/kg
after an unsuccessful therapeutic course of
antibiotics. 34 The dog subsequently exhibited
the typical prostaglandin side effects of
restlessness, panting, nest building, and it
vomited once. Within 60 minutes a purulent
discharge appeared from the vulva that
became progressively more mucous in nature
over a period of nine hours. In the subsequent
estrus period the dog was mated and produced
nine healthy puppies.
The other case was described as a typical
closed pyometra and was treated with one SQ
injection of PGF2a at a dose of 0.25 mg/kg.
Within 17 hours approximately one gallon of
purulent mucous discharge had been evacu-
ated. 27 Oxytocin was thereafter administered
which was followed by an increase in discharge
for a few hours. The vaginal discharge reoc-
curred 13 days later and was treated with two
doses of PGF2a (0.25 mg/kg SQ) given 24
hours apart, followed by antibiotics. The
discharge did not reoccur.
One report appears in the literature on the
ineffectiveness of prostaglandins for treatment
of uterine disease. 35
EMESIS AND DEFECATION
O,ne possible nonreproductive use of PGF2a
has been reported. 23 It was suggested that
PGF2a could· be used for the clinical induce-
ment of vomition and large intestine evacua-
tion in the dog. Defecation (83.3% of dogs)
without vomition occurred in dogs given a
dosage of 0.111 mg/kg. Emesis (87.5% of
dogs) and defecation (75% of dogs) were ob-
served in dogs given a dosage of greater than
or equal to 0.444 mg/kg with emesis occurring
1.6 to 2. 6 minutes after defecation.
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In effect, this use of PGF2a is taking advan-
tage of the side effects of prostaglandin
reported in reproductive applications.
However, the one major side effect that always
appears even before vomiting and defecation is
the increased respiratory rate, so respiratory
function would have to be carefully ascer-
tained before PGF2a use. The dosage would
also have to be accurately calculated to avoid
other undesirable effects. Possible advantages
to the use of PGF2a to induce vomition and
defecation are its rapid action, injectability,
and availability for the mixed practitioner
when an emergency emetic is needed in the
field.
Many potential nonreproductive veterinary
clincial applications of prostaglandins have
been suggested and initially investigated. 5 The
prostaglandins involved include PGF2a,
PGEl, PGE2 , PGI2 , and many varied
prostaglandin-active agents such as aspirin,
phenylbutazone, flunixin meglumine, theo-
phylline, vitamin E, selenium, and isoprotere-
nol. The scope of these potential uses is broad
and encompasses the treatment of the follow-
ing: disseminated intravascular coagulation;
endotoxemia; chronic vascular disease, such
as cardiomyopathies;' ischemia and sequellae,
such as shock, and laminitis; excessive
bleeding; bronchial asthma; toxic hepatitis;
and neoplastic metastasis.
The veterinary clinician should be aware of
the uses of prostaglandins that are currently
applicable as they may offer a source of viable
therapy or alternative treatment in small
animal medicine. In order to use prostaglan-
dins properly, with minimal deleterious un-
toward effects and successful administration, a
basic understanding of their mechanism of ac-
tion, physiological effects, and metabolism is
absolutely necessary. Recent advances in pro-
staglandin research have made nonreproduc-
tive veterinary uses potentially available and
the future portends further medical advances
based on prostaglandin physiology.
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